Advanced Accelerator Applications ^{Priced, Nasdaq: AAAP}

We are an innovative radiopharmaceutical company that develops, produces and commercializes MNM diagnostic and therapeutic products. MNM is a medical specialty that uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases such as cancer. We have built a leadership position in MNM in Europe by manufacturing and commercializing our broad portfolio of six diagnostic products for a number of clinical indications, and by selectively acquiring and integrating complementary businesses and assets. We leverage our leadership position, industry experience and know-how to pursue targeted R&D strategies. Our lead therapeutic candidate, Lutathera, is a novel compound that we are currently developing for the treatment of midgut NETs, a significant unmet medical need. Lutathera is a Lu-177-labeled somatostatin analogue peptide that has received orphan drug designation from the EMA and the FDA and is currently administered on a compassionate use and named patient basis for the treatment of NETs in nine European countries. We have identified that Lutathera has been used in over 2,900 patients and is currently in a pivotal Phase 3 trial for the treatment of progressive inoperable midgut NETs.